Michael Didocha Joins Telix as Chief Economical Officer,
MELBOURNE, Australia and INDIANAPOLIS, Aug. 31, 2021 (World NEWSWIRE) — Telix Prescription drugs Restricted (ASX: TLX, ‘Telix’, the ‘Company’) is happy to announce that Michael Didocha has joined the Corporation as Chief Economic Officer for the Americas area.
Michael joins with approximately 20 years’ working experience in lifetime science producing and commercialisation. Prior to becoming a member of Telix, Michael worked at Roche wherever he served for 16 a long time across different executive positions, which include as Director of Finance from 2017.
Mr. Didocha retains a Master of Business enterprise Administration in Finance and Accounting from Indiana University Kelley Faculty of Small business, and a Bachelor of Science in Mechanical Engineering from Georgia Institute of Engineering.
On signing up for Telix, Michael mentioned, “Any cancer prognosis today means that a patient is experiencing painful methods and uncertain outcomes. The guarantee of personalised radionuclide therapies to treat most cancers presents an thrilling risk to make a actual variance in people’s lives. It is crystal clear that Telix has each the expertise and state of mind to make these treatments a actuality. It is really an honor to be becoming a member of this group, and I am extremely psyched to be a section of this journey.”
Dr. Bernard Lambert, President, Telix Americas included, “With broad knowledge in strategic enterprise scheduling and economical accounting across everyday living sciences and healthcare products, Michael is a strong fit to guide our money functions in the Americas region. He joins at a pivotal second in the Company’s evolution, as we prepare for the start of illuccix®, with the hope that provides for US guys struggling with prostate cancer.”
About Telix Prescribed drugs Restricted
Telix is a biopharmaceutical corporation centered on the advancement of diagnostic and therapeutic merchandise making use of Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia with intercontinental operations in Belgium, Japan, and the United States. Telix is developing a portfolio of clinical-stage solutions that deal with substantial unmet health care want in oncology and rare health conditions. Telix is detailed on the Australian Securities Exchange (ASX: TLX). For extra details check out www.telixpharma.com and comply with Telix on Twitter (@TelixPharma) and LinkedIn.
Telix’s direct investigational merchandise, illuccix® (TLX591-CDx) for prostate most cancers imaging, has been approved for filing by the U.S. Fda,1 and is underneath priority evaluation by the Australian Therapeutic Items Administration (TGA).2 Telix is also progressing internet marketing authorisation apps for illuccix® in the European Union3 and Canada.4 None of Telix’s items have obtained a advertising authorisation in any jurisdiction.
Telix Media Call
Dr. Stewart Holmstrom
Telix Prescribed drugs Minimal
Director Company Communications
E mail: [email protected]
_______________________________
1 ASX disclosure 24/11/20.
2 ASX disclosure 14/04/21.
3 ASX disclosure 1/05/20.
4 ASX disclosure 16/12/20.
